Document:

EX-10.3

 Exhibit 10.3 

ELICIO THERAPEUTICS, INC. 

2021 OMNIBUS INCENTIVE COMPENSATION PLAN 

Effective as of the Effective Date (as defined below), the Elicio Therapeutics, Inc. 2021 Omnibus Incentive Compensation Plan (the
“Plan”) is hereby established. 
 The purpose of the Plan is to provide employees of Elicio Therapeutics, Inc. (the
“Company”) and its subsidiaries, certain consultants and advisors who perform services for the Company or its subsidiaries, and non-employee members of the Board of Directors of the Company
with the opportunity to receive grants of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, stock units, other stock-based awards, and cash awards. 

The Company believes that the Plan will encourage the Participants to contribute materially to the growth of the Company, thereby benefitting
the Company’s stockholders, and will align the economic interests of the Participants with those of the stockholders. 
 The Plan is a
successor to the Vedantra Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the “Prior Plan”). No additional grants shall be made under the Prior Plan after the Effective Date. Outstanding grants under the Prior Plan shall continue
in effect according to their terms, consistent with the Prior Plan. 
 Section 1.    Definitions 

The following terms shall have the meanings set forth below for purposes of the Plan: 

(a)    “Board” shall mean the Board of Directors of the Company. 

(b)    “Cash Award” shall mean a cash incentive payment awarded under this Plan as described under
Section 11. 
 (c)    “Cause” means, with respect to any Participant, and in the absence of an
Grant Instrument or other agreement between the Employer and the Participant that otherwise defines “cause”, (i) the Participant’s conviction of, or indictment for, any crime (whether or not involving the Employer), (A) constituting a
felony or (B) that has, or could reasonably be expected to result in, an adverse impact on the performance of the Participant’s duties to the Employer, or otherwise has, or could reasonably be expected to result in, an adverse impact on
the business or reputation of the Employer; (ii) conduct of the Participant, in connection with the Participant’s employment or service, that has resulted, or could reasonably be expected to result, in material injury to the business or
reputation of the Employer; (iii) any material violation of the policies of the Employer, including, but not limited to, those relating to sexual harassment or the disclosure or misuse of confidential information, or those set forth in the
manuals or statements of policy of the Employer; or (iv) willful neglect in the performance of the Participant’s duties for the Employer or willful or repeated failure or refusal to perform such duties. If, subsequent to a
Participant’s termination for any reason other than by the Employer for Cause, it is discovered that the Participant’s employment or service could have been terminated for Cause, such Participant’s

 
employment or service shall, at the discretion of the Committee, be deemed to have been terminated by the Employer for Cause for all purposes under this Plan, and the Participant shall be
required to disgorge to the Company all amounts received by the Participant in connection with awards granted under the Plan following such termination that would have been forfeited under the Plan had such termination been by the Employer for
Cause. In the event that there is a Grant Instrument, or other agreement between the Employer and the Participant, that defines Cause, Cause shall have the meaning provided in such Grant Instrument or agreement, and a termination by the Employer for
Cause hereunder shall not be deemed to have occurred unless all applicable notice and cure periods in such Grant Instrument or other agreement are complied with. 

(d)    “CEO” shall mean the Chief Executive Officer of the Company. 

(e)    Unless otherwise set forth in a Grant Instrument, a “Change of Control” shall be deemed to have
occurred if: 
 (i)    Any “person” (as such term is used in sections 13(d) and 14(d) of the Exchange Act)
becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than 50% of the voting power of the then
outstanding securities of the Company; provided that a Change of Control shall not be deemed to occur as a result of a transaction in which the Company becomes a subsidiary of another corporation and in which the stockholders of the Company,
immediately prior to the transaction, will beneficially own, immediately after the transaction, shares entitling such stockholders to more than 50% of all votes to which all stockholders of the parent corporation would be entitled in the election of
directors. 
 (ii)    The consummation of (A) a merger or consolidation of the Company with another corporation
where, immediately after the merger or consolidation, the stockholders of the Company, immediately prior to the merger or consolidation, will not beneficially own, in substantially the same proportion as ownership immediately prior to the merger or
consolidation, shares entitling such stockholders to more than 50% of all votes to which all stockholders of the surviving corporation would be entitled in the election of directors, or where the members of the Board, immediately prior to the merger
or consolidation, will not, immediately after the merger or consolidation, constitute a majority of the board of directors of the surviving corporation or (B) a sale or other disposition of all or substantially all of the assets of the Company.

 (iii)    A change in the composition of the Board over a period of 12 consecutive months or less such that a
majority of the Board members ceases, by reason of one or more contested elections, or threatened election contests, for Board membership, to be comprised of individuals who either (A) have been Board members continuously since the beginning of
such period or (B) have been elected or nominated for election as Board members during such period by at least a majority of the Board members described in clause (A) who were still in office at the time the Board approved such election or
nomination. 
 (iv)    The consummation of a complete dissolution or liquidation of the Company. 

  
 -2- 

 The Committee may modify the definition of Change of Control for a particular Grant as the
Committee deems appropriate to comply with section 409A of the Code or otherwise. Notwithstanding the foregoing, if a Grant constitutes deferred compensation subject to section 409A of the Code and the Grant provides for payment upon a Change of
Control, then, for purposes of such payment provisions, no Change of Control shall be deemed to have occurred upon an event described in items (i) – (iv) above unless the event would also constitute a change in ownership or effective control
of, or a change in the ownership of a substantial portion of the assets of, the Company under section 409A of the Code. 

(f)    “Code” shall mean the Internal Revenue Code of 1986, as amended, and the regulations promulgated
thereunder. 
 (g)    “Committee” shall mean the Compensation Committee of the Board or another
committee appointed by the Board to administer the Plan. The Committee shall also consist of directors who are “non-employee directors” as defined under Rule
16b-3 promulgated under the Exchange Act and “independent directors,” as determined in accordance with the independence standards established by the stock exchange on which the Company Stock is at
the time primarily traded. 
 (h)    “Company” shall mean Elicio Therapeutics, Inc., and shall include
its successors. 
 (i)    “Company Stock” shall mean common stock of the Company. 

(j)    “Disability” or “Disabled” shall mean, with respect to a Participant, unless
otherwise set forth in the Grant Instrument or other agreement between the Employer and the Participant that otherwise defines “disability”, that the Participant has been determined to be (1) disabled and entitled to receive benefits
under the applicable Employer’s long-term disability plan and (2) disabled under Treasury Regulation Section 1.409A-3(i)(4) or its successor. The date on which a Participant shall be deemed to
have incurred a Disability shall be the first date both requirements are satisfied as determined by the Committee or its designee. 

(k)    “Dividend Equivalent” shall mean an amount determined by multiplying the number of shares of
Company Stock subject to a Stock Unit or Other Stock-Based Award by the per-share cash dividend paid by the Company on its outstanding Company Stock, or the per-share
Fair Market Value of any dividend paid on its outstanding Company Stock in consideration other than cash. If interest is credited on accumulated divided equivalents, the term “Dividend Equivalent” shall include the accrued interest. 

(l)    “Effective Date” shall mean the business day immediately preceding the date at which the
registration statement for the public offering of the Company Stock is declared effective by the Securities and Exchange Commission and the Company Stock is priced for the public offering of such Company Stock, subject to approval of the Plan by the
stockholders of the Company. 
 (m)    “Employee” shall mean an employee of the Employer (including an
officer or director who is also an employee), but excluding any person who is classified by the Employer 

  
 -3- 

 
as a “contractor” or “consultant,” no matter how characterized by the Internal Revenue Service, other governmental agency or a court. Any change of characterization of an
individual by the Internal Revenue Service or any court or government agency shall have no effect upon the classification of an individual as an Employee for purposes of this Plan, unless the Committee determines otherwise. 

(n)    “Employed by, or providing service to, the Employer” shall mean employment or service as an
Employee, Key Advisor or member of the Board (so that, for purposes of exercising Options and SARs and satisfying conditions with respect to Stock Awards, Stock Units, Other Stock-Based Awards, and Cash Awards, a Participant shall not be considered
to have terminated employment or service until the Participant ceases to be an Employee, Key Advisor and member of the Board), unless the Committee determines otherwise. If a Participant’s relationship is with a subsidiary of the Company and
that entity ceases to be a subsidiary of the Company, the Participant will be deemed to cease employment or service when the entity ceases to be a subsidiary of the Company, unless the Participant transfers employment or service to an Employer. 

(o)    “Employer” shall mean the Company and its subsidiaries. 

(p)    “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended. 

(q)    “Exercise Price” shall mean the per share price at which shares of Company Stock may be purchased
under an Option, as designated by the Committee. 
 (r)    “Fair Market Value” shall mean: 

(i)    If the Company Stock is publicly traded, the Fair Market Value per share shall be determined as follows:
(A) if the principal trading market for the Company Stock is a national securities exchange, the closing sales price during regular trading hours on the relevant date or, if there were no trades on that date, the latest preceding date upon
which a sale was reported, or (B) if the Company Stock is not principally traded on any such exchange, the last reported sale price of a share of Company Stock during regular trading hours on the relevant date, as reported by the OTC Bulletin
Board. 
 (ii)    If the Company Stock is not publicly traded or, if publicly traded, is not subject to reported
transactions as set forth above, the Fair Market Value per share shall be determined by the Committee through any reasonable valuation method authorized under the Code. 

(iii)    If a Grant is made effective on the date that the registration statement for the initial public offering of the
Company Stock is declared effective by the Securities and Exchange Commission and the Company Stock is priced for the initial public offering of such Company Stock, then the Fair Market Value per share shall be equal to the per share price of
Company Stock offered to the public in such initial public offering. 

  
 -4- 

 (s)    “GAAP” shall mean United States Generally
Accepted Accounting Principles. 
 (t)    “Grant” shall mean an Option, SAR, Stock Award, Stock Unit,
Other Stock-Based Award, or Cash Award granted under the Plan. 
 (u)    “Grant Instrument” shall mean
the written agreement that sets forth the terms and conditions of a Grant, including all amendments thereto. 

(v)    “Incentive Stock Option” shall mean an Option that is intended to meet the requirements of an
incentive stock option under section 422 of the Code. 
 (w)    “Key Advisor” shall mean a consultant
or advisor of the Employer. 
 (x)    “Non-Employee Director”
shall mean a member of the Board who is not an Employee. 
 (y)    “Nonqualified Stock Option” shall
mean an Option that is not intended to be taxed as an incentive stock option under section 422 of the Code. 

(z)    “Option” shall mean an option to purchase shares of Company Stock, as described in Section 6.

 (aa)    “Other Stock-Based Award” shall mean any Grant based on, measured by or payable in Company
Stock (other than an Option, Stock Unit, Stock Award, or SAR), as described in Section 10. 

(bb)    “Participant” shall mean an Employee, Key Advisor or
Non-Employee Director designated by the Committee to participate in the Plan. 

(cc)    “Performance Goals” shall mean performance goals that may include, but are not limited to, one or
more of the following criteria: cash flow; free cash flow; earnings (including gross margin, earnings before interest and taxes, earnings before taxes, earnings before interest, taxes, depreciation, amortization and charges for stock-based
compensation, earnings before interest, taxes, depreciation and amortization, adjusted earnings before interest, taxes, depreciation and amortization and net earnings); earnings per share; growth in earnings or earnings per share; book value growth;
stock price; return on equity or average stockholder equity; total stockholder return or growth in total stockholder return either directly or in relation to a comparative group; return on capital; return on assets or net assets; revenue, growth in
revenue or return on sales; sales; expense reduction or expense control; expense to revenue ratio; income, net income or adjusted net income; operating income, net operating income, adjusted operating income or net operating income after tax;
operating profit or net operating profit; operating margin; gross profit margin; return on operating revenue or return on operating profit; regulatory filings; regulatory approvals, litigation and regulatory resolution goals; other operational,
regulatory or departmental objectives; budget comparisons; growth in stockholder value relative to established indexes, or another peer group or peer group index; development and implementation of strategic plans and/or organizational restructuring
goals; development and implementation of risk and crisis 

  
 -5- 

 
management programs; improvement in workforce diversity; compliance requirements and compliance relief; safety goals; productivity goals; workforce management and succession planning goals;
economic value added (including typical adjustments consistently applied from generally accepted accounting principles required to determine economic value added performance measures); measures of customer satisfaction, employee satisfaction or
staff development; development or marketing collaborations, formations of joint ventures or partnerships or the completion of other similar transactions intended to enhance the Company’s revenue or profitability or enhance its customer base;
merger and acquisitions; and other similar criteria as determined by the Committee. Performance goals applicable to a Grant shall be determined by the Committee, and may be established on an absolute or relative basis and may be established on a
corporate-wide basis or with respect to one or more business units, divisions, subsidiaries or business segments. Relative performance may be measured against a group of peer companies, a financial market index or other objective and quantifiable
indices. The Committee may make adjustments to the Performance Goals in its discretion. 

(dd)    “Plan” shall mean this Elicio Therapeutics, Inc. 2021 Omnibus Incentive Compensation Plan
(including any amendments, or amendments and restatements, thereto). 
 (ee)    “Prior Plan” shall mean
the Vedantra Pharmaceuticals, Inc. 2012 Equity Incentive Plan. 
 (ff)    “Restriction Period” shall
have the meaning given that term in Section 7(a). 
 (gg)    “SAR” shall mean a stock appreciation
right, as described in Section 9. 
 (hh)    “Stock Award” shall mean an award of Company Stock,
as described in Section 7. 
 (ii)    “Stock Unit” shall mean an award of a phantom unit
representing a share of Company Stock, as described in Section 8. 
 (jj)    “Substitute Awards”
shall have the meaning given that term in Section 4(b). 

Section 2.    Administration 

(a)    Committee. The Plan shall be administered and interpreted by the Committee; provided, however, that any
Grants to members of the Board must be authorized by a majority of the Board. The Committee may delegate authority to one or more subcommittees, as it deems appropriate. Subject to compliance with applicable law and the applicable stock exchange
rules, the Board, in its discretion, may perform any action of the Committee hereunder. To the extent that the Board, a subcommittee or the CEO, as described below administers the Plan, references in the Plan to the “Committee”
shall be deemed to refer to the Board or such subcommittee or the CEO. 
 (b)    Delegation to CEO. Subject to
compliance with applicable law and applicable stock exchange requirements, the Committee may delegate all or part of its authority and power to the CEO, as it deems appropriate, with respect to Grants to Employees or Key Advisors who are not
executive officers under section 16 of the Exchange Act. 

  
 -6- 

 (c)    Committee Authority. The Committee shall have the sole
authority to (i) determine the individuals to whom Grants shall be made under the Plan, (ii) determine the type, size, terms and conditions of the Grants to be made to each such individual, (iii) determine the time when the Grants
will be made and the duration of any applicable exercise or restriction period, including the criteria for vesting and exercisability and the acceleration of vesting and exercisability, (iv) amend the terms of any previously issued Grant,
subject to the provisions of Section 18 below, (v) determine and adopt terms, guidelines, and provisions, not inconsistent with the Plan and applicable law, that apply to individuals working or residing outside of the United States who
receive Grants under the Plan, (vi) correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Grant Instrument, and (vii) deal with any other matters arising under the Plan. 

(d)    Committee Determinations. The Committee shall have full power and express discretionary authority to
administer and interpret the Plan, to make factual determinations and to adopt or amend such rules, regulations, agreements and instruments for implementing the Plan and for the conduct of its business as it deems necessary or advisable, in its sole
discretion. The Committee’s interpretations of the Plan and all determinations made by the Committee pursuant to the powers vested in it hereunder shall be conclusive and binding on all persons having any interest in the Plan or in any awards
granted hereunder. All powers of the Committee shall be executed in its sole discretion, in the best interest of the Company, not as a fiduciary, and in keeping with the objectives of the Plan and need not be uniform as to similarly situated
individuals. 
 (e)    Indemnification. No member of the Committee or the Board, and no employee of the Company
shall be liable for any act or failure to act with respect to the Plan, except in circumstances involving his or her bad faith or willful misconduct, or for any act or failure to act hereunder by any other member of the Committee or employee or by
any agent to whom duties in connection with the administration of this Plan have been delegated. The Company shall indemnify members of the Committee and the Board and any agent of the Committee or the Board who is an employee of the Company or a
subsidiary against any and all liabilities or expenses to which they may be subjected by reason of any act or failure to act with respect to their duties on behalf of the Plan, except in circumstances involving such person’s bad faith or
willful misconduct. 
 Section 3.    Grants 

Grants under the Plan may consist of Options as described in Section 6, Stock Awards as described in Section 7, Stock Units as
described in Section 8, SARs as described in Section 9, Other Stock-Based Awards as described in Section 10, and Cash Awards as described in Section 11. All Grants shall be subject to the terms and conditions set forth herein and
to such other terms and conditions consistent with this Plan as the Committee deems appropriate and as are specified in writing by the Committee to the individual in the Grant Instrument. All Grants shall be made conditional upon the
Participant’s acknowledgement, in writing or by acceptance of the Grant, that all decisions and determinations of the Committee shall be final and binding on the Participant, his or her beneficiaries and any other person having or claiming an
interest under such Grant. Grants under a particular Section of the Plan need not be uniform as among the Participants. 

  
 -7- 

 Section 4.    Shares Subject to the Plan 

(a)    Shares Authorized. Subject to adjustment as described below in Sections 4(b) and 4(e) below, the aggregate
number of shares of Company Stock that may be issued or transferred under the Plan shall be 1,326,926 shares of Company Stock outstanding. The aggregate number of shares of Company Stock that may be issued or transferred under the Plan pursuant to
Incentive Stock Options shall not exceed 1,326,926 shares of Company Stock outstanding on the Effective Date. In addition, as of the first trading day of January during the term of the Plan (excluding any extensions), beginning with calendar year
2022, an additional positive number of shares of Company Stock shall be added to the number of shares of Company Stock authorized to be issued or transferred under the Plan, equal to four percent (4%) of the total number of shares of Company Stock
outstanding on the last trading day in December of the immediately preceding calendar year or such lesser amount as determined by the Board.  

(b)    Source of Shares; Share Counting. Shares issued or transferred under the Plan may be authorized but unissued
shares of Company Stock or reacquired shares of Company Stock, including shares purchased by the Company on the open market for purposes of the Plan. If and to the extent Options or SARs granted under the Plan, expire or are canceled, forfeited,
exchanged or surrendered without having been exercised, or if any Stock Awards, Stock Units or Other Stock-Based Awards are forfeited, terminated or otherwise not paid in full, the shares subject to such Grants shall again be available for purposes
of the Plan. If shares of Company Stock otherwise issuable under the Plan are surrendered in payment of the Exercise Price of an Option, then the number of shares of Company Stock available for issuance under the Plan shall be reduced only by the
net number of shares actually issued by the Company upon such exercise and not by the gross number of shares as to which such Option is exercised. Upon the exercise of any SAR under the Plan, the number of shares of Company Stock available for
issuance under the Plan shall be reduced by only by the net number of shares actually issued by the Company upon such exercise. If shares of Company Stock otherwise issuable under the Plan are withheld by the Company in satisfaction of the
withholding taxes incurred in connection with the issuance, vesting or exercise of any Grant or the issuance of Company Stock thereunder, then the number of shares of Company Stock available for issuance under the Plan shall be reduced by the net
number of shares issued, vested or exercised under such Grant, calculated in each instance after payment of such share withholding. To the extent any Grants are paid in cash, and not in shares of Company Stock, any shares previously subject to such
Grants shall again be available for issuance or transfer under the Plan. 
 (c)    Substitute Awards. Shares
issued or transferred under Grants made pursuant to an assumption, substitution or exchange for previously granted awards of a company acquired by the Company in a transaction (“Substitute Awards”) shall not reduce the number of
shares of Company Stock available under the Plan and available shares under a stockholder approved plan of an acquired company (as appropriately adjusted to reflect the transaction) may be used for Grants under the Plan and shall not reduce the
Plan’s share reserve (subject to applicable stock exchange listing and Code requirements). 

  
 -8- 

 (d)    Individual Limits. Subject to adjustment as described
below in Section 4(e), the following Grant limitations shall apply: 
 (i)    For Options, SARs, Stock Awards,
Stock Units and Other Stock-Based Awards (whether payable in Company Stock, cash or a combination of the two), the maximum number of shares of Company Stock for which such Grants may be made to any Employee or Key Advisor in any calendar year shall
not exceed 750,000 of the number of shares of Company Stock outstanding on the Effective Date in the aggregate. 

(ii)    The maximum aggregate grant date value of shares of Company Stock subject to Grants granted to any Non-Employee Director during any calendar year, taken together with any cash fees earned by such Non-Employee Director for services rendered during the calendar year, shall
not exceed $750,000 in total value. For purposes of this limit, the value of such Grants shall be calculated based on the grant date fair value of such Grants for financial reporting purposes. 

(iii)    Notwithstanding the foregoing, the individual limit described in subsection (i) shall be increased to two
times the otherwise applicable limit with respect to Grants that are made on or around the date of hire to a newly hired Employee. 

(e)    Adjustments. If there is any change in the number or kind of shares of Company Stock outstanding by reason
of (i) a stock dividend, spinoff, recapitalization, stock split, or combination or exchange of shares, (ii) a merger, reorganization or consolidation, (iii) a reclassification or change in par value, or (iv) any other
extraordinary or unusual event affecting the outstanding Company Stock as a class without the Company’s receipt of consideration, or if the value of outstanding shares of Company Stock is substantially reduced as a result of a spinoff or the
Company’s payment of an extraordinary dividend or distribution, the maximum number and kind of shares of Company Stock available for issuance under the Plan, the maximum number and kind of shares of Company Stock for which any individual may
receive Grants in any year, the number and kind of shares covered by outstanding Grants, the number and kind of shares issued and to be issued under the Plan, and the price per share or the applicable market value of such Grants shall be equitably
adjusted by the Committee to reflect any increase or decrease in the number of, or change in the kind or value of, the issued shares of Company Stock to preclude, to the extent practicable, the enlargement or dilution of rights and benefits under
the Plan and such outstanding Grants; provided, however, that any fractional shares resulting from such adjustment shall be eliminated. In addition, in the event of a Change of Control, the provisions of Section 13 of the Plan shall apply. Any
adjustments to outstanding Grants shall be consistent with section 409A or 424 of the Code, to the extent applicable. The adjustments of Grants under this Section 4(e) shall include adjustment of shares, Exercise Price of Stock Options, base
amount of SARs, performance goals or other terms and conditions, as the Committee deems appropriate. The Committee shall have the sole discretion and authority to determine what appropriate adjustments shall be made and any adjustments determined by
the Committee shall be final, binding and conclusive. 

  
 -9- 

 Section 5.    Eligibility for Participation 

(a)    Eligible Persons. All Employees and Non-Employee Directors shall be
eligible to participate in the Plan. Key Advisors shall be eligible to participate in the Plan if the Key Advisors render bona fide services to the Employer, the services are not in connection with the offer and sale of securities in a
capital-raising transaction and the Key Advisors do not directly or indirectly promote or maintain a market for the Company’s securities. 

(b)    Selection of Participants. The Committee shall select the Employees,
Non-Employee Directors and Key Advisors to receive Grants and shall determine the number of shares of Company Stock subject to a particular Grant in such manner as the Committee determines. 

Section 6.    Options 

The Committee may grant Options to an Employee, Non-Employee Director or Key Advisor upon such terms as
the Committee deems appropriate. The following provisions are applicable to Options: 
 (a)    Number of Shares.
The Committee shall determine the number of shares of Company Stock that will be subject to each Grant of Options to Employees, Non-Employee Directors and Key Advisors. 

(b)    Type of Option and Exercise Price. 

(i)    The Committee may grant Incentive Stock Options or Nonqualified Stock Options or any combination of the two, all
in accordance with the terms and conditions set forth herein. Incentive Stock Options may be granted only to employees of the Company or its parent or subsidiary corporations, as defined in section 424 of the Code. Nonqualified Stock Options may be
granted to Employees, Non-Employee Directors and Key Advisors. 
 (ii)    The
Exercise Price of Company Stock subject to an Option shall be determined by the Committee and shall be equal to or greater than the Fair Market Value of a share of Company Stock on the date the Option is granted, unless otherwise determined by the
Committee. However, an Incentive Stock Option may not be granted to an Employee who, at the time of grant, owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, or any parent or subsidiary
corporation of the Company, as defined in section 424 of the Code, unless the Exercise Price per share is not less than 110% of the Fair Market Value of a share of Company Stock on the date of grant. 

(c)    Option Term. The Committee shall determine the term of each Option. The term of any Option shall not exceed
ten years from the date of grant. However, an Incentive Stock Option that is granted to an Employee who, at the time of grant, owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, or any
parent or subsidiary corporation of the Company, as defined in section 424 of the Code, may not have a term that exceeds five years from the date of grant. 

  
 -10- 

 (d)    Exercisability of Options. Options shall become
exercisable in accordance with such terms and conditions, consistent with the Plan, as may be determined by the Committee and specified in the Grant Instrument. The Committee may accelerate the exercisability of any or all outstanding Options at any
time for any reason. 
 (e)    Grants to Non-Exempt Employees.
Notwithstanding the foregoing, Options granted to persons who are non-exempt employees under the Fair Labor Standards Act of 1938, as amended, may not be exercisable for at least six months after the date of
grant (except that such Options may become exercisable, as determined by the Committee, upon the Participant’s death, Disability or retirement, or upon a Change of Control or other circumstances permitted by applicable regulations). 

(f)    Termination of Employment or Service. Except as provided in the Grant Instrument, an Option may only be
exercised while the Participant is employed by, or providing services to, the Employer. The Committee shall determine in the Grant Instrument under what circumstances and during what time periods a Participant may exercise an Option after
termination of employment or service. 
 (g)    Exercise of Options. A Participant may exercise an Option that
has become exercisable, in whole or in part, by delivering a notice of exercise to the Company. The Participant shall pay the Exercise Price for an Option as specified by the Committee (i) in cash, (ii) unless the Committee determines
otherwise, by delivering shares of Company Stock owned by the Participant and having a Fair Market Value on the date of exercise at least equal to the Exercise Price or by attestation (on a form prescribed by the Committee) to ownership of shares of
Company Stock having a Fair Market Value on the date of exercise at least equal to the Exercise Price, (iii) by payment through a broker in accordance with procedures permitted by Regulation T of the Federal Reserve Board, (iv) if
permitted by the Committee, by withholding shares of Company Stock subject to the exercisable Option, which have a Fair Market Value on the date of exercise equal to the Exercise Price, or (v) by such other method as the Committee may approve.
Shares of Company Stock used to exercise an Option shall have been held by the Participant for the requisite period of time necessary to avoid adverse accounting consequences to the Company with respect to the Option. Payment for the shares to be
issued or transferred pursuant to the Option, and any required withholding taxes, must be received by the Company by the time specified by the Committee depending on the type of payment being made, but in all cases prior to the issuance or transfer
of such shares. 
 (h)    Limits on Incentive Stock Options. Each Incentive Stock Option shall provide that, if
the aggregate Fair Market Value of the Company Stock on the date of the grant with respect to which Incentive Stock Options are exercisable for the first time by a Participant during any calendar year, under the Plan or any other stock option plan
of the Company or a parent or subsidiary, exceeds $100,000, then the Option, as to the excess, shall be treated as a Nonqualified Stock Option. 

  
 -11- 

 Section 7.    Stock Awards 

The Committee may issue or transfer shares of Company Stock to an Employee, Non-Employee Director or
Key Advisor under a Stock Award, upon such terms as the Committee deems appropriate. The following provisions are applicable to Stock Awards: 

(a)    General Requirements. Shares of Company Stock issued or transferred pursuant to Stock Awards may be issued
or transferred for consideration or for no consideration, and subject to restrictions or no restrictions, as determined by the Committee. The Committee may, but shall not be required to, establish conditions under which restrictions on Stock Awards
shall lapse over a period of time or according to such other criteria as the Committee deems appropriate, including, without limitation, restrictions based upon the achievement of specific Performance Goals. The period of time during which the Stock
Awards will remain subject to restrictions will be designated in the Grant Instrument as the “Restriction Period.” 

(b)    Number of Shares. The Committee shall determine the number of shares of Company Stock to be issued or
transferred pursuant to a Stock Award and the restrictions applicable to such shares. 
 (c)    Requirement of
Employment or Service. If the Participant ceases to be employed by, or provide service to, the Employer during a period designated in the Grant Instrument as the Restriction Period, or if other specified conditions are not met, the Stock Award
shall terminate as to all shares covered by the Grant as to which the restrictions have not lapsed, and those shares of Company Stock must be immediately returned to the Company. The Committee may, however, provide for complete or partial exceptions
to this requirement as it deems appropriate. 
 (d)    Restrictions on Transfer and Legend on Stock Certificate.
During the Restriction Period, a Participant may not sell, assign, transfer, pledge or otherwise dispose of the shares of a Stock Award except under Section 16 below. Unless otherwise determined by the Committee, the Company will retain
possession of certificates for shares of Stock Awards until all restrictions on such shares have lapsed. Each certificate for a Stock Award, unless held by the Company, shall contain a legend giving appropriate notice of the restrictions in the
Grant. The Participant shall be entitled to have the legend removed from the stock certificate covering the shares subject to restrictions when all restrictions on such shares have lapsed. The Committee may determine that the Company will not issue
certificates for Stock Awards until all restrictions on such shares have lapsed. 
 (e)    Right to Vote and to
Receive Dividends. Unless the Committee determines otherwise, during the Restriction Period, the Participant shall have the right to vote shares of Stock Awards and to receive any dividends or other distributions paid on such shares, subject to
any restrictions deemed appropriate by the Committee, including, without limitation, the achievement of specific Performance Goals. Dividends with respect to Stock Awards that vest based on performance shall vest if and to the extent
that the underlying Stock Award vests, as determined by the Committee. 

  
 -12- 

 (f)    Lapse of Restrictions. All restrictions imposed on Stock
Awards shall lapse upon the expiration of the applicable Restriction Period and the satisfaction of all conditions, if any, imposed by the Committee. The Committee may determine, as to any or all Stock Awards, that the restrictions shall lapse
without regard to any Restriction Period. 
 Section 8.    Stock Units 

The Committee may grant Stock Units, each of which shall represent one hypothetical share of Company Stock, to an Employee, Non-Employee Director or Key Advisor upon such terms and conditions as the Committee deems appropriate. The following provisions are applicable to Stock Units: 

(a)    Crediting of Units. Each Stock Unit shall represent the right of the Participant to receive a share of
Company Stock or an amount of cash based on the value of a share of Company Stock, if and when specified conditions are met. All Stock Units shall be credited to bookkeeping accounts established on the Company’s records for purposes of the
Plan. 
 (b)    Terms of Stock Units. The Committee may grant Stock Units that vest and are payable if specified
Performance Goals or other conditions are met, or under other circumstances. Stock Units may be paid at the end of a specified performance period or other period, or payment may be deferred to a date authorized by the Committee. The Committee may
accelerate vesting or payment, as to any or all Stock Units at any time for any reason, provided such acceleration complies with section 409A of the Code. The Committee shall determine the number of Stock Units to be granted and the requirements
applicable to such Stock Units. 
 (c)    Requirement of Employment or Service. If the Participant ceases to be
employed by, or provide service to, the Employer prior to the vesting of Stock Units, or if other conditions established by the Committee are not met, the Participant’s Stock Units shall be forfeited. The Committee may, however, provide for
complete or partial exceptions to this requirement as it deems appropriate. 
 (d)    Payment With Respect to Stock
Units. Payments with respect to Stock Units shall be made in cash, Company Stock or any combination of the foregoing, as the Committee shall determine. 

Section 9.    Stock Appreciation Rights 

The Committee may grant SARs to an Employee, Non-Employee Director or Key Advisor separately or in
tandem with any Option. The following provisions are applicable to SARs: 
 (a)    General Requirements. The
Committee may grant SARs to an Employee, Non-Employee Director or Key Advisor separately or in tandem with any Option (for all or a portion of the applicable Option). Tandem SARs may be granted either at the
time the Option is granted or at any time thereafter while the Option remains outstanding; provided, however, that, in the case of an Incentive Stock Option, SARs may be granted only at the time of the grant of the Incentive Stock Option. The
Committee shall establish the base amount of the SAR at the time the SAR is granted. The base amount of each SAR shall be equal to or greater than the Fair Market 

  
 -13- 

 
Value of a share of Company Stock as of the date of grant of the SAR. The term of any SAR shall not exceed ten years from the date of grant. Notwithstanding the foregoing, in the event that on
the last business day of the term of a SAR, the exercise of the SAR is prohibited by applicable law, including a prohibition on purchases or sales of Company Stock under the Company’s insider trading policy, the term shall be extended for a
period of 30 days following the end of the legal prohibition, unless the Committee determines otherwise. 

(b)    Tandem SARs. In the case of tandem SARs, the number of SARs granted to a Participant that shall be
exercisable during a specified period shall not exceed the number of shares of Company Stock that the Participant may purchase upon the exercise of the related Option during such period. Upon the exercise of an Option, the SARs relating to the
Company Stock covered by such Option shall terminate. Upon the exercise of SARs, the related Option shall terminate to the extent of an equal number of shares of Company Stock. 

(c)    Exercisability. An SAR shall be exercisable during the period specified by the Committee in the Grant
Instrument and shall be subject to such vesting and other restrictions as may be specified in the Grant Instrument. The Committee may accelerate the exercisability of any or all outstanding SARs at any time for any reason. SARs may only be exercised
while the Participant is employed by, or providing service to, the Employer or during the applicable period after termination of employment or service as specified by the Committee. A tandem SAR shall be exercisable only during the period when the
Option to which it is related is also exercisable. 
 (d)    Grants to
Non-Exempt Employees. Notwithstanding the foregoing, SARs granted to persons who are non-exempt employees under the Fair Labor Standards Act of 1938, as
amended, may not be exercisable for at least six months after the date of grant (except that such SARs may become exercisable, as determined by the Committee, upon the Participant’s death, Disability or retirement, or upon a Change of Control
or other circumstances permitted by applicable regulations). 
 (e)    Value of SARs. When a Participant
exercises SARs, the Participant shall receive in settlement of such SARs an amount equal to the value of the stock appreciation for the number of SARs exercised. The stock appreciation for an SAR is the amount by which the Fair Market Value of the
underlying Company Stock on the date of exercise of the SAR exceeds the base amount of the SAR as described in subsection (a). 

(f)    Form of Payment. The appreciation in an SAR shall be paid in shares of Company Stock, cash or any
combination of the foregoing, as the Committee shall determine. For purposes of calculating the number of shares of Company Stock to be received, shares of Company Stock shall be valued at their Fair Market Value on the date of exercise of the SAR.

 Section 10.    Other Stock-Based Awards 

The Committee may grant Other Stock-Based Awards, which are awards (other than those described in Sections 6, 7, 8 and 9 of the Plan) that are
based on or measured by Company Stock, to any Employee, Non-Employee Director or Key Advisor, on such terms and conditions as the Committee shall determine. Other Stock-Based Awards may be awarded subject to
the achievement of Performance Goals or other criteria or other conditions and may be payable in cash, Company Stock or any combination of the foregoing, as the Committee shall determine. 

  
 -14- 

 Section 11.    Cash Awards 

The Committee may grant Cash Awards to Participants. The Committee shall determine the terms and conditions applicable to Cash Awards,
including the criteria for the vesting and payment of Cash Awards. Cash Awards shall be based on such measures as the Committee deems appropriate and need not relate to the value of shares of Company Stock. 

Section 12.    Dividend Equivalents 

The Committee may grant Dividend Equivalents in connection with Stock Units or Other Stock-Based Awards. Dividend Equivalents may be paid
currently or accrued as contingent cash obligations and may be payable in cash or shares of Company Stock, and upon such terms and conditions as the Committee shall determine. Dividend Equivalents with respect to Stock Units or Other Stock-Based
Awards that vest based on performance shall vest and be paid only if and to the extent the underlying Stock Units or Other Stock-Based Awards vest and are paid, as determined by the Committee. 

Section 13.    Consequences of a Change of Control 

(a)    Assumption of Outstanding Grants. Upon a Change of Control where the Company is not the surviving corporation
(or survives only as a subsidiary of another corporation), unless the Committee determines otherwise, all outstanding Grants that are not exercised or paid at the time of the Change of Control shall be assumed by, or replaced with grants that have
comparable terms by, the surviving corporation (or a parent or subsidiary of the surviving corporation). After a Change of Control, references to the “Company” as they relate to employment matters shall include the successor employer in
the transaction, subject to applicable law. 
 (b)    Vesting Upon Certain Terminations of Employment. Unless the
Grant Instrument provides otherwise, if a Participant’s employment or service is terminated by the Employer without Cause upon or within 12 months following a Change of Control, the Participant’s outstanding Grants shall become fully
vested as of the date of such termination; provided that if the vesting of any such Grants is based, in whole or in part, on performance, the applicable Grant Instrument shall specify how the portion of the Grant that becomes vested pursuant to this
Section 13(b) shall be calculated. 
 (c)    Other Alternatives. In the event of a Change of Control, if any
outstanding Grants are not assumed by, or replaced with grants that have comparable terms by, the surviving corporation (or a parent or subsidiary of the surviving corporation), the Committee may take any of the following actions with respect to any
or all outstanding Grants, without the consent of any Participant: (i) the Committee may determine that outstanding Stock Options and SARs shall automatically accelerate and become fully exercisable and the restrictions and conditions on
outstanding Stock Awards, Stock Units, Cash Awards, and Dividend Equivalents shall immediately lapse; (ii) the Committee may determine that Participants shall receive a payment in 

  
 -15- 

 
settlement of outstanding Stock Units, Cash Awards, or Dividend Equivalents, in such amount and form as may be determined by the Committee; (iii) the Committee may require that Participants
surrender their outstanding Stock Options and SARs in exchange for a payment by the Company, in cash or Company Stock as determined by the Committee, in an amount equal to the amount, if any, by which the then Fair Market Value of the shares of
Company Stock subject to the Participant’s unexercised Stock Options and SARs exceeds the Stock Option Exercise Price or SAR base amount, and (iv) after giving Participants an opportunity to exercise all of their outstanding Stock Options
and SARs, the Committee may terminate any or all unexercised Stock Options and SARs at such time as the Committee deems appropriate. Such surrender, termination or payment shall take place as of the date of the Change of Control or such other date
as the Committee may specify. Without limiting the foregoing, if the per share Fair Market Value of the Company Stock does not exceed the per share Stock Option Exercise Price or SAR base amount, as applicable, the Company shall not be required to
make any payment to the Participant upon surrender of the Stock Option or SAR. 
 (d)    Release. The Committee
may condition the payment made pursuant to the terms of the Plan as a result of a Change of Control upon the execution of a Release by the Participant in a form established by the Company. 

Section 14.    Deferrals 

The Committee may permit or require a Participant to defer receipt of the payment of cash or the delivery of shares that would otherwise be due
to such Participant in connection with any Grant. If any such deferral election is permitted or required, the Committee shall establish rules and procedures for such deferrals and may provide for interest or other earnings to be paid on such
deferrals. The rules and procedures for any such deferrals shall be consistent with applicable requirements of section 409A of the Code. 

Section 15.    Withholding of Taxes 

(a)    Required Withholding. All Grants under the Plan shall be subject to applicable United States federal
(including FICA), state and local, foreign country or other tax withholding requirements. The Employer may require that the Participant or other person receiving Grants or exercising Grants pay to the Employer an amount sufficient to satisfy such
tax withholding requirements with respect to such Grants, or the Employer may deduct from other wages and compensation paid by the Employer the amount of any withholding taxes due with respect to such Grants. 

(b)    Share Withholding. The Committee may permit or require the Employer’s tax withholding obligation with
respect to Grants paid in Company Stock to be satisfied by having shares withheld up to an amount that does not exceed the Participant’s applicable withholding tax rate for United States federal (including FICA), state and local, foreign
country or other tax liabilities. The Committee may, in its discretion, and subject to such rules as the Committee may adopt, allow Participants to elect to have such share withholding applied to all or a portion of the tax withholding obligation
arising in connection with any particular Grant. Unless the Committee determines otherwise, share withholding for taxes shall not exceed the Participant’s minimum applicable tax withholding amount. 

  
 -16- 

 Section 16.    Transferability of Grants 

(a)    Nontransferability of Grants. Except as described in subsection (b) below, only the Participant may
exercise rights under a Grant during the Participant’s lifetime. A Participant may not transfer those rights except (i) by will or by the laws of descent and distribution or (ii) with respect to Grants other than Incentive Stock
Options, pursuant to a domestic relations order. When a Participant dies, the personal representative or other person entitled to succeed to the rights of the Participant may exercise such rights. Any such successor must furnish proof satisfactory
to the Company of his or her right to receive the Grant under the Participant’s will or under the applicable laws of descent and distribution. 

(b)    Transfer of Nonqualified Stock Options. Notwithstanding the foregoing, the Committee may provide, in a Grant
Instrument, that a Participant may transfer Nonqualified Stock Options to family members, or one or more trusts or other entities for the benefit of or owned by family members, consistent with the applicable securities laws, according to such terms
as the Committee may determine; provided that the Participant receives no consideration for the transfer of an Option and the transferred Option shall continue to be subject to the same terms and conditions as were applicable to the Option
immediately before the transfer. 
 Section 17.    Requirements for Issuance or Transfer of Shares 

No Company Stock shall be issued or transferred in connection with any Grant hereunder unless and until all legal requirements applicable to
the issuance or transfer of such Company Stock have been complied with to the satisfaction of the Committee. The Committee shall have the right to condition any Grant on the Participant’s undertaking in writing to comply with such restrictions
on his or her subsequent disposition of the shares of Company Stock as the Committee shall deem necessary or advisable, and certificates representing such shares may be legended to reflect any such restrictions. Certificates representing shares of
Company Stock issued or transferred under the Plan may be subject to such stop-transfer orders and other restrictions as the Committee deems appropriate to comply with applicable laws, regulations and interpretations, including any requirement that
a legend be placed thereon. 
 Section 18.    Amendment and Termination of the Plan 

(a)    Amendment. The Board may amend or terminate the Plan at any time; provided, however, that the Board shall not
amend the Plan without stockholder approval if such approval is required in order to comply with the Code or other applicable law, or to comply with applicable stock exchange requirements. 

(b)    No Repricing of Options or SARs. Except in connection with a corporate transaction involving the Company
(including, without limitation, any stock dividend, distribution (whether in the form of cash, Company Stock, other securities or property), stock split, extraordinary cash dividend, recapitalization, change in control, reorganization, merger,
consolidation, split-up, spin-off, combination, repurchase or exchange of shares of Company Stock 

  
 -17- 

 
or other securities, or similar transactions), the Company may not, without obtaining stockholder approval, (i) amend the terms of outstanding Stock Options or SARs to reduce the Exercise
Price of such outstanding Stock Options or base price of such SARs, (ii) cancel outstanding Stock Options or SARs in exchange for Stock Options or SARs with an Exercise Price or base price, as applicable, that is less than the Exercise Price or
base price of the original Stock Options or SARs or (iii) cancel outstanding Stock Options or SARs with an Exercise Price or base price, as applicable, above the current stock price in exchange for cash or other securities. 

(c)    Termination of Plan. The Plan shall terminate on the day immediately preceding the tenth anniversary of its
Effective Date, unless the Plan is terminated earlier by the Board or is extended by the Board with the approval of the stockholders. 

(d)    Termination and Amendment of Outstanding Grants. A termination or amendment of the Plan that occurs after a
Grant is made shall not materially impair the rights of a Participant unless the Participant consents or unless the Committee acts under Section 19(f) below. The termination of the Plan shall not impair the power and authority of the Committee
with respect to an outstanding Grant. Whether or not the Plan has terminated, an outstanding Grant may be terminated or amended under Section 19(f) below or may be amended by agreement of the Company and the Participant consistent with the
Plan. 
 Section 19.    Miscellaneous 

(a)    Grants in Connection with Corporate Transactions and Otherwise. Nothing contained in the Plan shall be
construed to (i) limit the right of the Committee to make Grants under the Plan in connection with the acquisition, by purchase, lease, merger, consolidation or otherwise, of the business or assets of any corporation, firm or association,
including Grants to employees thereof who become Employees, or (ii) limit the right of the Company to grant stock options or make other awards outside of the Plan. The Committee may make a Grant to an employee of another corporation who becomes
an Employee by reason of a corporate merger, consolidation, acquisition of stock or property, reorganization or liquidation involving the Company, in substitution for a stock option or a stock award grant made by such corporation. Notwithstanding
anything in the Plan to the contrary, the Committee may establish such terms and conditions of the new Grants as it deems appropriate, including setting the Exercise Price of Options or the base price of SARs at a price necessary to retain for the
Participant the same economic value as the prior options or rights. 
 (b)    Governing Document. The Plan shall
be the controlling document. No other statements, representations, explanatory materials or examples, oral or written, may amend the Plan in any manner. The Plan shall be binding upon and enforceable against the Company and its successors and
assigns. 
 (c)    Funding of the Plan. The Plan shall be unfunded. The Company shall not be required to
establish any special or separate fund or to make any other segregation of assets to assure the payment of any Grants under the Plan. 

  
 -18- 

 (d)    Rights of Participants. Nothing in the Plan shall entitle
any Employee, Non-Employee Director, Key Advisor or other person to any claim or right to receive a Grant under the Plan. Neither the Plan nor any action taken hereunder shall be construed as giving any
individual any rights to be retained by or in the employ of the Employer or any other employment rights. 
 (e)    No
Fractional Shares. No fractional shares of Company Stock shall be issued or delivered pursuant to the Plan or any Grant. Except as otherwise provided under the Plan, the Committee shall determine whether cash, other awards or other property
shall be issued or paid in lieu of such fractional shares or whether such fractional shares or any rights thereto shall be forfeited or otherwise eliminated. 

(f)    Compliance with Law. 

(i)    The Plan, the exercise of Options and SARs and the obligations of the Company to issue or transfer shares of
Company Stock under Grants shall be subject to all applicable laws and regulations, and to approvals by any governmental or regulatory agency as may be required. With respect to persons subject to section 16 of the Exchange Act, it is the intent of
the Company that the Plan and all transactions under the Plan comply with all applicable provisions of Rule 16b-3 or its successors under the Exchange Act. In addition, it is the intent of the Company that
Incentive Stock Options comply with the applicable provisions of section 422 of the Code, and that, to the extent applicable, Grants comply with the requirements of section 409A of the Code. To the extent that any legal requirement of section 16 of
the Exchange Act or section 422 or 409A of the Code as set forth in the Plan ceases to be required under section 16 of the Exchange Act or section 422 or 409A of the Code, that Plan provision shall cease to apply. The Committee may revoke any Grant
if it is contrary to law or modify a Grant to bring it into compliance with any valid and mandatory government regulation. The Committee may also adopt rules regarding the withholding of taxes on payments to Participants. The Committee may, in its
sole discretion, agree to limit its authority under this Section. 
 (ii)    The Plan is intended to comply with the
requirements of section 409A of the Code, to the extent applicable. Each Grant shall be construed and administered such that the Grant either (A) qualifies for an exemption from the requirements of section 409A of the Code or (B) satisfies
the requirements of section 409A of the Code. If a Grant is subject to section 409A of the Code, (I) distributions shall only be made in a manner and upon an event permitted under section 409A of the Code, (II) payments to be made upon a
termination of employment or service shall only be made upon a “separation from service” under section 409A of the Code, (III) unless the Grant specifies otherwise, each installment payment shall be treated as a separate payment for
purposes of section 409A of the Code, and (IV) in no event shall a Participant, directly or indirectly, designate the calendar year in which a distribution is made except in accordance with section 409A of the Code. 

(iii)    Any Grant that is subject to section 409A of the Code and that is to be distributed to a Key Employee (as
defined below) upon separation from service shall be administered so that any distribution with respect to such Grant shall be postponed for six months following the date of the Participant’s separation from service, if required by section 409A
of the 

  
 -19- 

 
Code. If a distribution is delayed pursuant to section 409A of the Code, the distribution shall be paid within 15 days after the end of the six-month
period. If the Participant dies during such six-month period, any postponed amounts shall be paid within 90 days of the Participant’s death. The determination of Key Employees, including the number and
identity of persons considered Key Employees and the identification date, shall be made by the Committee or its delegate each year in accordance with section 416(i) of the Code and the “specified employee” requirements of section 409A of
the Code. 
 (iv)    Notwithstanding anything in the Plan or any Grant Instrument to the contrary, each Participant
shall be solely responsible for the tax consequences of Grants under the Plan, and in no event shall the Company or any subsidiary or affiliate of the Company have any responsibility or liability if a Grant does not meet any applicable requirements
of section 409A of the Code. Although the Company intends to administer the Plan to prevent taxation under section 409A of the Code, the Company does not represent or warrant that the Plan or any Grant complies with any provision of federal, state,
local or other tax law. 
 (g)    Establishment of Subplans. The Committee may from time to time establish one or
more sub-plans under the Plan for purposes of satisfying the requirements of local law or to obtain more favorable tax or other treatment with respect to grants to participants who reside or work outside of
the United States. The Committee shall establish such sub-plans by adopting supplements to the Plan setting forth such additional terms and conditions not otherwise inconsistent with the Plan as the Committee
shall deem necessary. All supplements adopted by the Committee shall be deemed to be part of the Plan. 

(h)    Clawback Rights. Subject to the requirements of applicable law, and to the extent the Company has not
implemented a clawback or recoupment policy outside of the Plan that is applicable to the Participant, if a Participant breaches any restrictive covenant agreement between the Participant and the Employer (which may be, but is not required to be,
set forth in any Grant Instrument) (i) by contributing to an event in which the Company is required to prepare an accounting restatement due to its material noncompliance with any financial reporting requirement under United States securities
laws either while employed by, or providing service to, the Employer or within three years thereafter, or (ii) otherwise engages in activities that constitute Cause either while employed by, or providing service to, the Employer or within
twelve (12) months thereafter, all Grants held by the Participant shall terminate, and the Company may rescind any exercise of an Option or SAR and the vesting of any other Grant and delivery of shares upon such exercise or vesting (including
pursuant to dividends and Dividend Equivalents), as applicable on such terms as the Committee shall determine, including the right to require that in the event of any such rescission, (A) the Participant shall return to the Company the shares
received upon the exercise of any Option or SAR and/or the vesting and payment of any other Grant (including pursuant to dividends and Dividend Equivalents) or, (B) if the Participant no longer owns the shares, the Participant shall pay to the
Company the amount of any gain realized or payment received as a result of any sale or other disposition of the shares (or, in the event the Participant transfers the shares by gift or otherwise without consideration, the Fair Market Value of the
shares on the date of the breach of the restrictive covenant agreement (including a Participant’s Grant Instrument containing restrictive covenants) or activity constituting Cause), net of the price originally paid by the Participant for the
shares. Payment by the Participant shall be made in such 

  
 -20- 

 
manner and on such terms and conditions as may be required by the Committee. The Employer shall be entitled to set off against the amount of any such payment any amounts otherwise owed to the
Participant by the Employer. In addition, all Grants under the Plan shall be subject to any applicable share trading policies and other policies that may be implemented by the Board from time to time. 

(i)    Governing Law. The validity, construction, interpretation and effect of the Plan and Grant Instruments
issued under the Plan shall be governed and construed by and determined in accordance with the laws of the State of Delaware, without giving effect to the conflict of laws provisions thereof. 

  
 -21- 

 ELICIO THERAPEUTICS, INC. 

2021 OMNIBUS INCENTIVE COMPENSATION PLAN 

NONQUALIFIED STOCK OPTION GRANT AGREEMENT 

This NONQUALIFIED STOCK OPTION GRANT AGREEMENT (the “Agreement”), dated as of [●] (the “Date of
Grant”), is delivered by Elicio Therapeutics, Inc. (the “Company”) to [●] (the “Participant”). 

RECITALS 
 The Elicio
Therapeutics, Inc. 2021 Omnibus Incentive Compensation Plan (the “Plan”) provides for the grant of stock options to purchase shares of Company stock (“Company Stock”). The Committee has decided to make this
nonqualified stock option Grant as an inducement for the Participant to promote the best interests of the Company and its stockholders. This Agreement is made pursuant to the Plan and is subject in its entirety to all applicable provisions of the
Plan. Capitalized terms used herein and not otherwise defined will have the meanings set forth in the Plan. 
 1.    Grant of
Option. Subject to the terms and conditions set forth in this Agreement and in the Plan, the Company hereby grants to the Participant a nonqualified stock option (the “Option”) to purchase [●] shares of Company Stock (each
a “Share”, and together the “Shares”) at an Exercise Price of $[●] per Share. The Option shall become exercisable according to Section 2 below. 

2.    Exercisability of Option. 

(a)    Subject to the terms of this Section 2, the Option shall become vested according to the following schedule
(each a “Vesting Date”), provided that the Participant continues to be employed by, or provide service to, the Employer from the Date of Grant until the applicable Vesting Date. 

 

			
	 VESTING DATE
	  	 VESTING AMOUNT

		  	
		  	
		  	

 (b)    The vesting and exercisability of the Option is cumulative, but shall not exceed
100% of the Shares subject to the Option. If the terms set forth on in Section 2(a) would produce fractional Shares, the number of Shares for which the Option becomes vested and exercisable shall be rounded down to the nearest whole Share and
the fractional Shares will be accumulated so that the resulting whole Shares will be included in the number of Shares for which the Option becomes vested and exercisable on the last Vesting Date. 

 (c)    Except as otherwise provided in a written employment agreement or
severance agreement entered into by and between the Participant and the Employer, in the event of a Change of Control before the Option is fully vested and exercisable, the provisions of the Plan applicable to a Change of Control shall apply to the
Option, and, in the event of a Change of Control, the Committee may take such actions with respect to the vesting and exercisability of the Option as it deems appropriate pursuant to the Plan. 

3.    Term of Option. 

(a)    The Option shall have a term of ten years from the Date of Grant and shall terminate at the expiration of that
period, unless it is terminated at an earlier date pursuant to the provisions of this Agreement or the Plan. Notwithstanding the foregoing, in the event that on the last business day of the term of the Option, the exercise of the Option is
prohibited by applicable law, including a prohibition on purchases or sales of Company Stock under the Company’s insider trading policy, the term of the Option shall be extended for a period of 30 days following the end of the legal
prohibition, unless the Committee determines otherwise. 
 (b)    The Option shall automatically terminate upon the
happening of the first of the following events: 
 (i)    The expiration of the 90-day period after the Participant ceases to be employed by, or provide service to, the Employer, if the termination is for any reason other than Disability, death or Cause. 

(ii)    The expiration of the one-year period after the Participant
ceases to be employed by, or provide service to, the Employer on account of the Participant’s Disability. 

(iii)    The expiration of the one-year period after the
Participant ceases to be employed by, or provide service to, the Employer, if the Participant dies while employed by, or providing service to, the Employer or the Participant dies within 90 days after the Participant ceases to be so employed or to
provide services to the Employer for any reason other than Disability, death or Cause. 
 (iv)    The
date on which the Participant ceases to be employed by, or provide service to, the Employer for Cause. In addition, notwithstanding the prior provisions of this Section 3, if the Participant engages in conduct that constitutes Cause after the
Participant’s employment or service terminates, the Option shall immediately terminate. 
 Notwithstanding the foregoing, in no event may the Option be
exercised after the date that is immediately before the tenth anniversary of the Date of Grant, except as provided under Section 3(a) above. Any portion of the Option that is not exercisable at the time the Participant ceases to be employed by,
or provide service to, the Employer shall immediately terminate. 
 4.    Exercise Procedures. 

(a)    Subject to the provisions of Sections 2 and 3 above, the Participant may exercise part or all of the exercisable
Option by giving the Company or its delegate written notice of 

  
 -2- 

 
intent to exercise in a form permitted by the Company, specifying the number of shares of Company Stock as to which the Option is to be exercised and such other information as the Company or its
delegate may require. 
 (b)    At such time as the Committee shall determine, the Participant shall pay the Exercise
Price (i) in cash, (ii) if permitted by the Committee in its sole discretion, by delivering shares of Company Stock owned by the Participant, which shall be valued at their Fair Market Value on the date of exercise, or by attestation (in
accordance with procedures prescribed by the Company) to ownership of shares of Company Stock having a Fair Market Value on the date of exercise at least equal to the Exercise Price, (iii) by payment through a broker in accordance with
procedures permitted by Regulation T of the Federal Reserve Board, (iv) if permitted by the Committee in its sole discretion, by surrendering shares of Company Stock subject to the exercisable Option for an appreciation distribution payable in
Shares with a Fair Market Value on the date of exercise equal to the dollar amount by which the then Fair Market Value of the Shares subject to the surrendered portion exceeds the aggregate Exercise Price payable for the Shares (“net
exercise”), or (v) by such other method as the Committee may approve, to the extent permitted by applicable law. The Committee may impose from time to time such limitations as it deems appropriate on the use of shares of Company Stock to
exercise the Option. 
 (c)    The obligation of the Company to deliver Shares upon exercise of the Option shall be
subject to all applicable laws, rules, and regulations and such approvals by governmental agencies as may be deemed appropriate by the Committee, including such actions as Company counsel shall deem necessary or appropriate to comply with relevant
securities laws and regulations. 
 (d)    All obligations of the Company under this Agreement shall be subject to the
rights of the Employer as set forth in the Plan to withhold amounts required to be withheld for any taxes, if applicable. The Participant shall be required to pay to the Employer, or make other arrangements satisfactory to the Employer to provide
for the payment of, any federal, state, local or other taxes that the Employer is required to withhold with respect to the Option. At such time as the Committee may determine, the Participant may elect to satisfy any tax withholding obligation of
the Employer with respect to the Option by having Shares withheld to satisfy the applicable withholding tax rate for FICA, federal, state, local and other tax liabilities. 

(e)    Upon exercise of the Option (or portion thereof), the Option (or portion thereof) will terminate and cease to be
outstanding. 
 5.    Restrictions on Exercise. Except as the Committee may otherwise permit pursuant to the Plan, only the
Participant may exercise the Option during the Participant’s lifetime and, after the Participant’s death, the Option shall be exercisable (subject to the limitations specified in the Plan) solely by the legal representatives of the
Participant, or by the person who acquires the right to exercise the Option by will or by the laws of descent and distribution, to the extent that the Option is exercisable pursuant to this Agreement. 

6.    Grant Subject to Plan Provisions. This Grant is made pursuant to the Plan, the terms of which are incorporated herein by
reference, and in all respects shall be interpreted in accordance with the Plan. The grant and exercise of the Option are subject to the provisions of the Plan and 

  
 -3- 

 
to interpretations, regulations and determinations concerning the Plan established from time to time by the Committee in accordance with the provisions of the Plan, including, but not limited to,
provisions pertaining to (a) rights and obligations with respect to withholding taxes, (b) the registration, qualification or listing of the Shares, (c) changes in capitalization of the Company and (d) other requirements of
applicable law. The Committee shall have the authority to interpret and construe the Option pursuant to the terms of the Plan, and its decisions shall be conclusive as to any questions arising hereunder. 

7.     No Employment or Other Rights. The grant of the Option shall not confer upon the Participant any right to be retained by or
in the employ or service of any Employer and shall not interfere in any way with the right of any Employer to terminate the Participant’s employment or service at any time. The right of any Employer to terminate at will the Participant’s
employment or service at any time for any reason is specifically reserved. 
 8.     No Stockholder Rights. Neither the
Participant, nor any person entitled to exercise the Participant’s rights in the event of the Participant’s death, shall have any of the rights and privileges of a stockholder with respect to the Shares subject to the Option, until
certificates for Shares have been issued upon the exercise of the Option. 
 9.    Assignment and Transfers. Except as the
Committee may otherwise permit pursuant to the Plan, the rights and interests of the Participant under this Agreement may not be sold, assigned, encumbered or otherwise transferred except, in the event of the death of the Participant, by will or by
the laws of descent and distribution. In the event of any attempt by the Participant to alienate, assign, pledge, hypothecate, or otherwise dispose of the Option or any right hereunder, except as provided for in this Agreement, or in the event of
the levy or any attachment, execution or similar process upon the rights or interests hereby conferred, the Company may terminate the Option by notice to the Participant, and the Option and all rights hereunder shall thereupon become null and void.
The rights and protections of the Company hereunder shall extend to any successors or assigns of the Company and to the Company’s parents, subsidiaries, and affiliates. This Agreement may be assigned by the Company without the
Participant’s consent. 
 10.    Applicable Law; Jurisdiction. The validity, construction, interpretation and effect of this
Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to the conflicts of laws provisions thereof. Any action arising out of, or relating to, any of the provisions of this Agreement
shall be brought only in the United States District Court for the District of Massachusetts, or if such court does not have jurisdiction or will not accept jurisdiction, in any court of general jurisdiction in Boston, Massachusetts, and the
jurisdiction of such court in any such proceeding shall be exclusive. Notwithstanding the foregoing sentence, on and after the date a Participant receives shares of Company Stock hereunder, the Participant will be subject to the jurisdiction
provision set forth in the Company’s bylaws.  
 11.    Notice. Any notice to the Company provided for in this
instrument shall be addressed to the Company in care of the General Counsel and, except as provided in Section 14, any notice to the Participant shall be addressed to such Participant at the current address shown on the payroll of the Employer.
Except as provided in Section 14, any notice shall be delivered by hand or 

  
 -4- 

 
enclosed in a properly sealed envelope addressed as stated above, registered and deposited, postage prepaid, in a post office regularly maintained by the United States Postal Service or by the
postal authority of the country in which the Participant resides or to an internationally recognized expedited mail courier. 

12.    Recoupment Policy. The Participant agrees that, subject to the requirements of applicable law, the Option, and the right to
receive and retain any Shares, or the amount of any gain realized or payment received as a result of any sale or other disposition of the Shares, covered by this Agreement, shall be subject to rescission, cancellation or recoupment, in whole or
part, if and to the extent so provided under the Plan and any “clawback” or similar policy of the Company in effect on the Date of Grant or that may be established thereafter. By accepting the Option, the Participant agrees and
acknowledges that the Participant is obligated to cooperate with, and provide any and all assistance necessary to, the Company to recover or recoup any such Option or Shares or amounts paid under the Option subject to clawback or recoupment pursuant
to such policy, listing standard or law. Such cooperation and assistance shall include, but is not limited to, executing, completing and submitting any documentation necessary to recover or recoup any such Option or Shares or amount paid from the
Participant’s accounts, or pending or future compensation or Awards under the Plan. 
 13.    Application of Section 409A of the
Code. The Award under this Agreement is intended to be exempt from section 409A of the Code and to the extent this Agreement is subject to section 409A of the Code, it will in all respects be administered in accordance with section 409A of the
Code. 
 14.    Electronic Delivery. The Employer may, in its sole discretion, deliver any documents relating to the
Participant’s Option and the Participant’s participation in the Plan, or future Awards that may be granted under the Plan, by electronic means or request the Participant’s consent to participate in the Plan by electronic means. The
Participant hereby consents to receive such documents by electronic delivery and, if requested, agrees to participate in the Plan through an on-line or electronic system established and maintained by the
Employer or another third-party designated by the Company. 
 15.    Severability. If any provision of this Agreement is held to
be unenforceable, illegal or invalid for any reason, the unenforceability, illegality or invalidity will not affect the remaining provisions of the Agreement, and the Agreement is to be construed and enforced as if the unenforceable, illegal or
invalid provision had not been inserted, and the provisions so held to be invalid, unenforceable or otherwise illegal shall be reformed to the extent (and only to the extent) necessary to make it enforceable, valid and legal. 

16.    Waiver. The waiver by the Company with respect to the Participant’s (or any other participant’s) compliance of any
provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by such party of a provision of this Agreement. 

17.    Amendment. Except as permitted by the Plan, this Agreement may not be amended, modified, terminated or otherwise altered
except by the written consent of the Company and the Participant. 

  
 -5- 

 18.    Counterparts. This Agreement may be executed in one or more counterparts,
each of which will be deemed to be an original but all of which together will constitute one and the same instrument. 

19.    Binding Effect; No Third Party Beneficiaries. This Agreement shall be binding upon and inure to the benefit of the Company
and the Participant and each of their respective heirs, representatives, successors and permitted assigns. This Agreement shall not confer any rights or remedies upon any person other than the Company and the Participant and each of their respective
heirs, representatives, successor and permitted assigns. 
 [Signature Page Follows] 

  
 -6- 

 IN WITNESS WHEREOF, the Company has caused an officer to execute this Agreement, and the
Participant has executed this Agreement, effective as of the Date of Grant. 
  

	
	ELICIO THERAPEUTICS, INC.
	
	  

	Name:
	Title:

 I hereby accept the Option described in this Agreement, and I agree to be bound by the terms of the Plan and this
Agreement. I hereby further agree that all decisions and determinations of the Committee shall be final and binding. 
  

	
	Participant:                                    
                            
	Date:                                     
                                     

  
 -7- 

 ELICIO THERAPEUTICS, INC. 

2021 OMNIBUS INCENTIVE COMPENSATION PLAN 

RESTRICTED STOCK UNIT AGREEMENT 

This RESTRICTED STOCK UNIT AGREEMENT (the “Agreement”), dated as of [●] (the “Date of Grant”), is
delivered by Elicio Therapeutics, Inc. (the “Company”) to [●] (the “Participant”). 

RECITALS 
 The Elicio
Therapeutics, Inc. 2021 Omnibus Incentive Compensation Plan (the “Plan”) provides for the grant of restricted stock units in accordance with the terms and conditions of the Plan. The Committee has decided to make this Grant of
restricted stock units as an inducement for the Participant to promote the best interests of the Company and its stockholders. This Agreement is made pursuant to the Plan and is subject in its entirety to all applicable provisions of the Plan.
Capitalized terms used herein and not otherwise defined will have the meanings set forth in the Plan. 
 1.    Grant of Restricted
Stock Units. Subject to the terms and conditions set forth in this Agreement and in the Plan, the Company hereby grants the Participant [●] restricted stock units, subject to the restrictions set forth below and in the Plan (the
“Stock Units”). Each Stock Unit represents the right of the Participant to receive a share of common stock of the Company (“Company Stock”), an amount of cash based on the value of a share of Company Stock, or any
combination of the foregoing, as determined by the Committee, if and when the specified conditions are met in Section 3 below, and on the applicable payment date set forth in Section 5 below. 

2.    Stock Unit Account. Stock Units represent hypothetical shares of Company Stock, and not actual shares of stock. The Company
shall establish and maintain a Stock Unit account, as a bookkeeping account on its records, for the Participant and shall record in such account the number of Stock Units granted to the Participant. No shares of Company Stock shall be issued to the
Participant at the time the Grant is made, and the Participant shall not be, and shall not have any of the rights or privileges of, a stockholder of the Company with respect to any Stock Units recorded in the Stock Unit account. The Participant
shall not have any interest in any fund or specific assets of the Company by reason of this award or the Stock Unit account established for the Participant. 

  

 3.    Vesting. 

(a) Subject to the terms of this Section 3, the Stock Units shall become vested according to the following schedule (each, a
“Vesting Date”), provided that the Participant continues to be employed by, or provide service to, the Employer from the Date of Grant until the applicable Vesting Date: 

 

			
	 Vesting Date
	  	 Number of Vested Stock Units

	                    	  	                    
	                    	  	                    
	                    	  	                    

(b)    The vesting of the Stock Units shall be cumulative, but shall not exceed 100% of the Stock Units. If the foregoing
schedule would produce fractional Stock Units, the number of Stock Units that vest shall be rounded down to the nearest whole Stock Unit and the fractional Stock Units will be accumulated so that the resulting whole Stock Units will be included in
the number of Stock Units that become vested on the last Vesting Date. 
 (c)    Except as otherwise provided in a
written employment agreement or severance agreement entered into by and between the Participant and the Employer, in the event of a Change of Control before all of the Stock Units vest in accordance with Section 3(a) above, the provisions of
the Plan applicable to a Change of Control shall apply to the Stock Units, and, in the event of a Change of Control, the Committee may take such actions with respect to the vesting of the Stock Units as it deems appropriate pursuant to the Plan.

 4.    Termination of Stock Units. Except as set forth in this Agreement, if the Participant ceases to be employed by, or
provide service to, the Employer for any reason before all of the Stock Units vest, any unvested Stock Units shall automatically terminate and shall be forfeited as of the date of the Participant’s termination of employment or service. No
payment shall be made with respect to any unvested Stock Units that terminate as described in this Section 4. 
 5.    Payment
of Stock Units and Tax Withholding. 
 (a)    If and when the Stock Units vest, the Company shall issue to the
Participant one share of Company Stock for each vested Stock Unit, or an amount of cash equal to the value of a share of Company Stock for each vested Stock Unit, or a combination of the foregoing, subject to applicable tax withholding obligations.
Subject to Sections 5(b) and 13 below, payment shall be made within 30 days after the applicable Vesting Date. 

(b)    All obligations of the Company under this Agreement shall be subject to the rights of the Employer as set forth in
the Plan to withhold amounts required to be withheld for any taxes, if applicable. If permitted by the Committee, at the time of payment in accordance with Section 5(a) above, or if applicable, at the time the Stock Units vest, the number of
shares issued to the Participant may be reduced by a number of shares of Company Stock with a Fair Market Value (measured as of the Vesting Date) equal to an amount of the FICA, federal income, state, local and other tax liabilities required by law
to be withheld with respect to the payment of the Stock Units. To the extent not withheld in accordance with the immediately preceding sentence, the Participant shall be required to pay to the Employer, or make other arrangements satisfactory to the
Employer to provide for the payment of, any federal, state, local or other taxes that the Employer is required to withhold with respect to the Stock Units. 

(c)    The obligation of the Company to deliver Company Stock shall also be subject to the condition that if at any time
the Board shall determine in its discretion that the listing, registration or qualification of the shares upon any securities exchange or under any state or 

  
 2 

 
federal law, or the consent or approval of any governmental regulatory body is necessary or desirable as a condition of, or in connection with, the issuance of shares, the shares may not be
issued in whole or in part unless such listing, registration, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Board. The issuance of shares, if any, to the Participant pursuant to
this Agreement is subject to any applicable taxes and other laws or regulations of the United States or of any state, municipality or other country having jurisdiction thereof. 

6.    No Stockholder Rights; Dividend Equivalents. Neither the Participant, nor any person entitled to receive payment in the event
of the Participant’s death, shall have any of the rights and privileges of a stockholder with respect to shares of Company Stock, including voting or dividend rights, until certificates for shares have been issued upon payment of Stock Units.
The Participant acknowledges that no election under Section 83(b) of the Code is available with respect to Stock Units. Notwithstanding the foregoing, the Committee may grant to the Participant Dividend Equivalents on the shares underlying
the Stock Units prior to the Vesting Date, which shall be credited to the Stock Unit account for the Participant and will be paid or distributed in in accordance with this Agreement and the Plan. 

7.    Grant Subject to Plan Provisions. This Grant is made pursuant to the Plan, the terms of which are incorporated herein by
reference, and in all respects shall be interpreted in accordance with the Plan. The grant and payment of the Stock Units are subject to the provisions of the Plan and to interpretations, regulations and determinations concerning the Plan
established from time to time by the Committee in accordance with the provisions of the Plan, including, but not limited to, provisions pertaining to (a) rights and obligations with respect to withholding taxes, (b) the registration,
qualification or listing of the shares of Company Stock, (c) changes in capitalization of the Company and (d) other requirements of applicable law. The Committee shall have the authority to interpret and construe the Stock Units pursuant
to the terms of the Plan, and its decisions shall be conclusive as to any questions arising hereunder. 
 8.    No Employment or
Other Rights. The Grant of the Stock Units shall not confer upon the Participant any right to be retained by or in the employ or service of any Employer and shall not interfere in any way with the right of any Employer to terminate the
Participant’s employment or service at any time. The right of any Employer to terminate at will the Participant’s employment or service at any time for any reason is specifically reserved. The obligations of the Company hereunder will be
that of an unfunded and unsecured promise of the Company to deliver, for each vested Stock Unit, payment as provided in Section 5 and the rights of the Participant will be no greater than that of an unsecured general creditor. No assets of the
Company will be held or set aside as security for the obligations of the Company hereunder. 
 9.    Assignment and Transfers.
Except as the Committee may otherwise permit pursuant to the Plan, the rights and interests of the Participant under this Agreement may not be sold, assigned, encumbered or otherwise transferred except, in the event of the death of the Participant,
by will or by the laws of descent and distribution. In the event of any attempt by the Participant to alienate, assign, pledge, hypothecate, or otherwise dispose of the Stock Units or any right hereunder, except as provided for in this Agreement, or
in the event of the levy or any attachment, execution or similar process upon the rights or interests hereby conferred, the 

  
 3 

 Company may terminate the Stock Units by notice to the Participant, and the Stock Units and all rights
hereunder shall thereupon become null and void. The rights and protections of the Company hereunder shall extend to any successors or assigns of the Company and to the Company’s parents, subsidiaries, and affiliates. This Agreement may be
assigned by the Company without the Participant’s consent. 
 10.    Applicable Law; Jurisdiction. The validity,
construction, interpretation and effect of this Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to the conflicts of laws provisions thereof. Any action arising out of, or
relating to, any of the provisions of this Agreement shall be brought only in the United States District Court for the District of Massachusetts, or if such court does not have jurisdiction or will not accept jurisdiction, in any court of general
jurisdiction in Boston, Massachusetts, and the jurisdiction of such court in any such proceeding shall be exclusive. Notwithstanding the foregoing sentence, on and after the date a Participant receives shares of Company Stock hereunder, the
Participant will be subject to the jurisdiction provision set forth in the Company’s bylaws.  

11.    Notice. Any notice to the Company provided for in this instrument shall be addressed to the Company in care of the General
Counsel at the corporate headquarters of the Company, and except as provided in Section 14, any notice to the Participant shall be addressed to such Participant at the current address shown on the payroll of the Employer. Except as provided in
Section 14, any notice shall be delivered by hand, or enclosed in a properly sealed envelope addressed as stated above, registered and deposited, postage prepaid, in a post office regularly maintained by the United States Postal Service or by
the postal authority of the country in which the Participant resides or to an internationally recognized expedited mail courier. 

12.    Recoupment Policy. The Participant agrees that, subject to the requirements of applicable law, the Stock Units, and the
right to receive and retain any Company Stock or cash payments covered by this Agreement, shall be subject to rescission, cancellation or recoupment, in whole or part, if and to the extent so provided under the Plan, or any “clawback” or
similar policy of the Company in effect on the Date of Grant or that may be established thereafter. By accepting the Stock Units, the Participant agrees and acknowledges that the Participant is obligated to cooperate with, and provide any and all
assistance necessary to, the Company to recover or recoup any such Stock Units or shares or amounts paid under the Stock Units subject to clawback or recoupment pursuant to such policy, listing standard or law. Such cooperation and assistance shall
include, but is not limited to, executing, completing and submitting any documentation necessary to recover or recoup any such Stock Units or shares or amount paid from the Participant’s accounts, or pending or future compensation or Awards
under the Plan. 
 13.    Application of Section 409A of the Code. The Award under this Agreement is intended to be exempt
from or otherwise comply with the provisions of Section 409A of the Code, as amended, and the regulations and other guidance promulgated or issued thereunder (“Section 409A of the Code”). Notwithstanding the
foregoing, if the Stock Units constitute “deferred compensation” under Section 409A of the Code and the Stock Units become vested and settled upon the Participant’s termination of employment, payment with respect to the Stock
Units shall be delayed for a period of six months after the Participant’s termination of employment if the 

  
 4 

 
Participant is a “specified employee” as defined under Section 409A of the Code and if required pursuant to Section 409A of the Code. If payment is delayed, the Stock Units
shall be settled and paid within thirty (30) days after the date that is six (6) months following the Participant’s termination of employment. Payments with respect to the Stock Units may only be paid in a manner and upon an event
permitted by Section 409A of the Code, and each payment under the Stock Units shall be treated as a separate payment, and the right to a series of installment payments under the Stock Units shall be treated as a right to a series of separate
payments. In no event shall the Participant, directly or indirectly, designate the calendar year of payment. The Company may change or modify the terms of this Agreement without the Participant’s consent or signature if the Company determines,
in its sole discretion, that such change or modification is necessary for purposes of compliance with or exemption from the requirements of Section 409A of the Code. Notwithstanding the previous sentence, the Company may also amend the Plan or
this Agreement or revoke the Stock Units to the extent permitted by the Plan. Notwithstanding the foregoing in this Section 13, the Company makes no representations and/or warranties with respect to compliance with Section 409A of the
Code, and the Participant recognizes and acknowledges that Section 409A of the Code could potentially impose upon the Participant certain taxes and/or interest charges for which the Participant is and shall remain solely responsible. 

14.    Electronic Delivery. The Employer may, in its sole discretion, deliver any documents relating to the Participant’s
Stock Units and the Participant’s participation in the Plan, or future Awards that may be granted under the Plan, by electronic means or request the Participant’s consent to participate in the Plan by electronic means. The Participant
hereby consents to receive such documents by electronic delivery and, if requested, agrees to participate in the Plan through an on-line or electronic system established and maintained by the Employer or
another third-party designated by the Employer. 
 15.    Severability. If any provision of this Agreement is held to be
unenforceable, illegal or invalid for any reason, the unenforceability, illegality or invalidity will not affect the remaining provisions of the Agreement, and the Agreement is to be construed and enforced as if the unenforceable, illegal or invalid
provision had not been inserted, and the provisions so held to be invalid, unenforceable or otherwise illegal shall be reformed to the extent (and only to the extent) necessary to make it enforceable, valid and legal. 

16.    Waiver. The waiver by the Company with respect to the Participant’s (or any other participant’s) compliance of any
provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by such party of a provision of this Agreement. 

17.    Amendment. Except as permitted by the Plan, this Agreement may not be amended, modified, terminated or otherwise altered
except by the written consent of the Company and the Participant. 
 18.    Counterparts. This Agreement may be executed in one
or more counterparts, each of which will be deemed to be an original but all of which together will constitute one and the same instrument. 

  
 5 

 19.    Binding Effect; No Third Party Beneficiaries. This Agreement shall be
binding upon and inure to the benefit of the Company and the Participant and each of their respective heirs, representatives, successors and permitted assigns. This Agreement shall not confer any rights or remedies upon any person other than the
Company and the Participant and each of their respective heirs, representatives, successor and permitted assigns. 
 [Signature Page
Follows] 

  
 6 

 IN WITNESS WHEREOF, the Company has caused its duly authorized officer to execute this
Agreement, and the Participant has executed this Agreement, effective as of the Date of Grant. 
  

	
	ELICIO THERAPEUTICS, INC.
	
	  

	Name:
	Title:

 I hereby accept the award of Stock Units described in this Agreement, and I agree to be bound by the terms of the Plan
and this Agreement. I hereby agree that all decisions and determinations of the Committee with respect to the Stock Units shall be final and binding. 
  

					
	 Date
	 		  	 Participant

  
 7SECOND AMENDMENT TO THE

AMENDED AND RESTATED

PATENT AND TECHNOLOGY LICENSE AGREEMENT

 

THIS SECOND AMENDMENT TO THE AMENDED AND RESTATED PATENT AND TECHNOLOGY LICENSE AGREEMENT (this “Second Amendment”) is entered into as of July 12, 2021 (the “Second Amendment Date”), by and between CELL SCIENCE HOLDING LTD., a limited liability company organized and existing under the laws of the Republic of Cyprus, having its principal office at Panteli Katelari 18A, Agios Ioannis, Limassol, 3012 Cyprus (“Cell Science”), and BAKHU HOLDINGS, CORP., a Nevada corporation, having its principal office at One World Trade Center, Suite 130, Long Beach, CA 90831, United States (“Bakhu”). 

 

Premises

 

A.Cell Science and Bakhu are parties to that certain Patent and Technology License Agreement dated December 20, 2018 (the “Original License Agreement”), which on December 31, 2019, was merged with and into the Amended and Restated Patent and Technology License Agreement (together, the “Restated License Agreement”). In the Restated License Agreement, Cell Science is referred to as the Licensor and Bakhu is referred to as the Licensee.  

 

B.In Pursuant to the Original License Agreement and the Restated License Agreement, in consideration of the grant of the license by Cell Science to Bakhu, Bakhu issued 210,000,000 shares of Common Stock to Cell Science. 

 

C.The Restated License Agreement was amended by that certain Amendment to the Amended and Restated Patent and Technology License Agreement entered into as of September 22, 2020. (the “September 2020 Amendment”). 

 

D.In November 2020, subject to the September 2020 Amendment, Cell Science transferred the 210,000,000 shares of Common Stock to Inter-M Traders FZ LLE (“Inter-M”) and Mentone, Ltd. (“Mentone”).   

 

E.The Restated License Agreement was further amended by that certain First Amendment of the Amendment to the Amended and Restated Patent and Technology License Agreement entered into as of February 8, 2021 (the “First Amendment”), which increased the Released Shares as defined in the September 2020 Amendment, from 20,000,000 shares to 26,000,000 shares. 

 

F.Immediately prior to the Second Amendment Date, Inter-M is the record and beneficial owner of 20,000,000 Released Shares and 102,571,429 Contingent Shares as such term is defined in the September 2020 Amendment and Mentone is the record and beneficial owner of 6,000,000 Released Shares and 81,428,571 Contingent Shares. 

Page 1

G.The Parties by this Second Amendment now desire to further amend the Restated License Agreement, as subsequently amended, all of which are merged into a single, integrated agreement that are together hereinafter referred to as the “Integrated License Agreement.” 

 

Agreement

 

NOW, THEREFORE, upon the foregoing premises, which are incorporated herein by reference, and for and in consideration of the mutual promises and covenants set forth herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties agree as follows: 

 

1.Efficacy Demonstration; Revised Exhibit 1. Exhibit 1 attached to this Amendment entitled “Revised Laboratory Testing Requirements for Section 4.2” (“Efficacy Demonstration”) fully replaces and supersedes the Exhibit 1 heretofore attached to the Second Amended License Agreement.  

 

2.Ratification of Integrated License Agreement. Except as expressly amended by the foregoing, the parties ratify and confirm the Integrated License Agreement.   

 

IN WITNESS WHEREOF, each Party hereto has caused its duly authorized representatives to execute this Second Amendment to the Integrated License Agreement as of the Second Amendment Date.

 

LICENSOR:

 

CELL SCIENCE HOLDING LTD.

  

 

 

By: /s/ Petros Charalambous

Petros Charalambous

Director and Secretary

 

Date: July 12, 2021

 

 

LICENSEE:

 

BAKHU HOLDINGS, CORP.

  

 

By: /s/ Thomas K. Emmitt

Thomas K. Emmitt

President and CEO

 

Date: July 12, 2021

Page 2

EXHIBIT 1 to

Integrated License Agreement

July 12, 2021

SECOND REVISED LABORATORY TESTING REQUIREMENTS 

FOR SECTION 4.2 OF 

INTEGRATED LICENSE AGREEMENT

 

(Further Revised July 8, 2021)

 

 

Planned demonstration of application of proprietary science and processes at commercial scale within standards of agreed efficacy.

 

Cell Science and Bakhu are parties to that certain Patent and Technology License Agreement, dated December 20, 2018, which on December 31, 2019, was merged with and into the Amended and Restated Patent and Technology License Agreement (together, the “Amended License Agreement”). In the License Agreement, Cell Science is referred to as the Licensor and Bakhu is referred to as the Licensee. 

 

The Amended License Agreement was amended by that certain Amendment to the Amended and Restated Patent and Technology License Agreement entered into as of September 22, 2020, and that certain [Second] Amendment to the Amended and Restated Patent and Technology License Agreement entered into in November 2020.

 

The Parties are further amending the Amended License Agreement as amended by the  [Second] Amendment to the Amended and Restated Patent and Technology License Agreement by a Second Amendment to the Amended and Restated Patent and  Technology License Agreement adopting these Second Revised Laboratory Testing Requirements, all of which are merged into a single, integrated agreement that are together hereinafter referred to as the “Integrated License Agreement.”

 

This Second Revised Laboratory Testing Requirements for Section 4.2 supersedes and replaces in full previous versions of Exhibit 1 to the Integrated License Agreement.

 

To this specific end, the Parties agree that the “laboratory testing” referred to in Section 4.2 of the Integrated License Agreement will be initiated when Dr. Whitton and his team have satisfactorily prepared the R and D lab environment and fine-tuned the supporting equipment for the Cell Science Process, with Dr. Whitton providing written notice to Bakhu when the Efficacy Demonstration has commenced.  The laboratory testing will have the following attributes and targets delivering the results set forth below. The delivery of such results will demonstrate, for purposes of this Exhibit and the terms of the Agreement, acceptable “efficacy” of the proprietary science underlying the Licensed Science for commercial and licensing purposes, which means that the laboratory testing confirms that the licensed proprietary science and processes can be used routinely by qualified personnel in accordance with the prescribed specification for specialized equipment, suitable facilities, formulations, and processes to consistently, predictably, repeatedly and economically produce commercial quantities of the specified cannabinoids  (hereinafter the “Efficacy Demonstration”).

Exhibit 1 - Page 1

EXHIBIT 1 to

Integrated License Agreement

July 12, 2021

The “Science Team” as referenced in this Exhibit consists of professional scientists from, Dr. Peter Whitton, the inventor.

 

Overall objective: The end-product, in quantity, projected production costs, and quality will meet the representative claims, oral and written, summarized below:

 

Representative Claims and Proposed Actions and Duties of the Inventor:

 

1.General Claim: The Licensed Science and processes may be utilized to dissect a cell of a cannabis donor plant that has measurable THC (tetrahydrocannabinol) and CBD (cannabidiol) percentage levels, and thereafter grow duplicate cells in a laboratory commercial application over a combined cycle of 18 to [24] weeks, so that each grow cycle, using five (5), 1,000 liter biorectors: 

 

(a)loaded from the same existing or new seed culture batch, 

 

(b)operated under the same temperatures, lighting, ventilation, vacuum, equipment calibration, drying times, temperature, and all other material specifications,   

 

(c)harvested via membrane filtration or centrifugal separation to produce a liquid product concentrate, 

 

(d)producing, after concentration by filtering or centrifuging and drying, at least 18 kg (approximately 39 lbs.) of concentrate cells and media culture food and nutrients per bioreactor and 90 kg (approximately 198 lbs.) for the five (5) bioreactors,  

 

(e)with further processing producing the volume of cannabinoids in kg per bioreactor harvest that mirror the same percentage of THC and CBD as the donor cell (Example: 20% THC in Donor plan yields 3.6 kg of cannabinoids), and 

 

(f)achieving a predictable cost of consumables, disposables and utilities (excluding capital expenditures, labor, admin, and operational expenses) of $0.10 per gram.  

 

Tests will be conducted separately for each bioreactor.

 

2.Specific Claim: The Licensed Science may be utilized to dissect a donor cell from a cannabis plant, with a laboratory tested and verified beginning THC and CBD levels, re-produce that cell to a flask volume within six to eight weeks, and thereafter reproduce that cell culture from flask to a seed culture volume of 10 liters. The mature seed culture cells will be added to five (5), 1,000 liter bioreactors sequentially, with the 10 liter of cells for the seed culture containing the identical cell profile as the original donor cell. 

Exhibit 1 - Page 2

EXHIBIT 1 to

Integrated License Agreement

July 12, 2021

3.Specific Claim: The Cell Science process of selecting a targeted cell from a cannabis plant with a third-party affirmed THC and CBD percentage presence, and growing that targeted cell forward in multiple steps, including growing the cells in a proprietary bioreactor within a proprietary pod under controlled conditions, will produce a cell culture that, after harvesting a 1000 liter bioreactor,  will produce a concentrate that has a proportional representation in terms of kg of cannabinoids of the donor plant identified THC/CBD cannabinoids.  The Licensed Science processes may be utilized to add a 100 liter seed culture to a one (1), 900 liter medium culture and, in approximately six weeks of cell growth process (the “Production Cycle”), harvest through a filtration or centrifugal process approximately 100 liters of production cells concentrate that is then laboratory dried to approximately 18 kg (39 lbs.)  or more of dry cell concentrate, media culture nutrients and food, or at the discretion of the Science Team, is extracted, to yield the volume of Cannabinoids defined by the formula: 18 times original THC/CBD percentage of donor plant equals the end product expressed in kg. If it is not possible to dry the whole amount, then  a sample will be taken and dried according to the US Pharmacopoeia protocol for calculating dried weight. The end product will contain the same THC and CBD percentages of cannabinoids as the donor cell and the cell profiles in the 10-liter seed culture originally added to the each of the 1,000-liter bioreactors at the beginning of the Production Cycle. (Section 2 and 3 combined as the “Efficacy Demonstration”.  To further clarify, if the donor plant from which the Science Team harvests the initial seed cells  had 20% THC/4% CBD (the Donor Cell Profile), the Specific Claim is that in a 1000 liter batch, the Cell Science process will yield 3.6 kg of pure cannabinoids that mirror the donor plant cell profile.( Yield = 20% X 18 kg (our predicted business model concentrate yield sans sugar or nutrient material ) or 3.6 kg of pure cannabinoids)  The Science Team will conduct and document the Efficacy Demonstration in processes in five bioreactors to satisfy the Efficacy Demonstration requirement. 

 

4.Specific Claim: The Science Team, and their retained professionals can (a) design a commercial production laboratory that will be equipped with ten (10), 1,000 liter disposable bioreactor bladders and all necessary supporting equipment for the laboratory and production facility (as needed for  sterilization mixing, seed culturing, filtration, drying, and packing) and thereafter oversee the construction and testing of such a facility, including designing and buying or building necessary support equipment, and (b) coincidently, prepare all necessary handbooks and supporting proprietary and non-proprietary process documentation that will result in a documented demonstration of the commercialization of the science process more fully described in Section 1 above. 

 

5.Specific Duty: The Science Team and their retained professionals will administer any testing, adjusting, and operational exercise required to ready the laboratory and production facility for this specific Efficacy Demonstration. 

Exhibit 1 - Page 3

EXHIBIT 1 to

Integrated License Agreement

July 12, 2021

6.Specific Duty: The Science Team will select the plant(s) to be utilized as the donor plants for the Efficacy Demonstration from a resource provided by an affiliate of the Licensee. 

 

7.Specific Duty: The Science Team will dissect and test the “donor” cell for the level of THC and CBD. 

 

8.Specific Duty: The Science Team will distribute selected cells to a third-party laboratory to affirm the percentage of THC and CBD in the donor cells at the initiation of the culture growing process, with the laboratory test cost paid by the affiliate of the Licensee. 

 

9.Specific Duty: The Science Team will dissect and grow the flask of cells, which will then be utilized to grow the cells to be utilized as the seed culture for the bioreactors, which will be loaded, processed, and tested separately, and when this growth process is complete, begin the cell production cycle. 

 

10.Specific Duty: At the end of the Production Cycle for each bioreactor, the Science Team `will harvest the production cells from each bioreactor separately, filter the harvested cells, dry the harvested cells, certify that the test in each bioreactor has been conducted in accordance with the specifications of this Revised Laboratory Testing Requirements, and test the end product cells to ascertain if the desired result as set forth in Section 1., has been achieved for each bioreactor. 

 

11.Specific Duty: The Science Team will make available to a third-party test laboratory of Licensee’s choosing sufficient quantities of the produced harvested and produced cannabinoids from all five (5) bioreactors comprising the Efficacy Demonstration to allow that third party testing laboratory to verify the stated claims and representations of the Science Team laboratory tested results.  

 

12.Specific Agreement: Only the third-party laboratory tested results will be utilized to ascertain if the claims of the Science Team are verified. 

 

13.Specific Detail on the Acceptable “Standard Result”: The efficacy demonstration of the Licensed Science and process as set forth generally in Section 1 above is intended to achieve the following results:  

 

(a) the percentage of THC in the donor plant multiplied by 18 kg (the target weight of dried cells (“Quantity Standard”); 

 

(b)the cells produced, harvested and dried during the full cycle of the Licensed Science process from each bioreactor harvest contain the targeted volume of cannabinoids expressed in kg that mirror the same levels of THC and CBD as the donor cells utilizing the formula: 18 times original THC/CBD percentage of donor plant equals the end product expressed in kg, with this result from  

Exhibit 1 - Page 4

EXHIBIT 1 to

Integrated License Agreement

July 12, 2021

each bioreactor and all five (5) bioreactors affirmed by a third-party testing laboratory (“Concentration Standard”); and 

 

(c) this result is achieved at a projected utility and supplies (estimates of KWH for operation of the equipment will be added to the actual material costs using market prices for the bulk acquisition of utility and consumables per bioreactor and all five (5) bioreactors, plus the cost of disposables and consumables to determine the “projected utility and supplies cost” without computation of admin,  labor, capital expenditures, or prorated leasehold expenses) cost of $0.10 per gram (“Cost Standard”).  

 

The achievement of the Quantity, Concentration, and Cost Standards results set forth in Section 17(a) through (c) above, for purposes of the Integrated License Agreement and the Efficacy Demonstration, is the “Standard Result” claimed by the inventor and acceptable to the Parties.

 

14.Specific Agreement: Any result with a variance in (a) a shortfall in the achieving the Quantity Standard, ( b) a shortfall in achieving the Concentration Standard, or (c) an overage above the Cost Standard will trigger a pro-rata reduction in the cash and Common Stock consideration from Licensee to Licensor as set forth in the table below. 

 

15.Specific Notice: Results at significant variation with the “Standard Result” devalue the science for licensing and production purposes, and depending on the variation, substantially reduce the commercial viability of the Licensed Science or render it commercially valueless. 

 

16.Specific Agreement: The Parties agree to the table below as the formula for determination of the amount, if any of the reduction of the amount payable in cash and equity to Licensor under the Integrated License Agreement. 

 

17.License Consideration to Licensor. The number of Contingent Shares as defined in the Integrated License Agreement and the amount of the cash payment provided in Section 4.1 and 4.2, respectively, of the Integrated License Agreement (together, the “License Consideration”), will each be reduced if less than the claimed Quantity or Concentration Standards or more than the claimed Cost Standard is achieved in the particular bioreactor and five (5) bioreactor production cycles. To determine the applicable adjustment, (i) the actual Quantity Standard produced in the test will be divided by 90 kg and the result increased by 10%; (ii) the actual Concentration Standard of the cannabinoids produced will be measured in kg, and this amount will be determined by the formula: 18 times original THC/CBD percentage of donor plant equals the end product of cannabinoids expressed in kg,  for each bioreactor, and this efficacy target for concentration will be 75% of this figure; and (iii) and the Cost Standard of  $0.10 gram will be subtracted from the calculated cost per gram of the particular the test and the difference divided by $0.10, reduced by 15%. The percentage resulting from the arithmetic average of the above weighted results will  

Exhibit 1 - Page 5

EXHIBIT 1 to

Integrated License Agreement

July 12, 2021

yield the results for that particular test (together, ”Percentage Achievement”). The Science Team will select a sample from each of the five bioreactors comprising the Efficacy Demonstration to be used by the third-party lab to determine the Percentage Achievement for each bioreactor separately and for all bioreactors as a group. The arithmetic average of five bioreactors meeting the Standard Results will constitute the Percentage Achievement for the test. The percentage of the License Consideration to be delivered to the Licensor for the Percentage Achievement is set forth in the table below.

 

	Percentage Achievement of at least

	100%

	90%

	80%

	70%

	60%

	50%

	Percent of Contingent Shares Released

	100%

	100%

	90%

	70%

	60%

	50%

 

(a)The Standard Result requires that each bioreactor as well as all five (5) bioreactors as a whole yield a Percentage Achievement of 50% or better in order to require payment and release of the agreed cash and Contingent Shares. 

Exhibit 1 - Page 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]